Business, energy, technology, markets and global industry news from Business News Today

oral GLP-1

PharmaDeviceNews oral GLP-1
Pharma & Biotech

Can Ascletis Pharma challenge injectable GLP-1 leaders with oral ASC30?

Oral GLP-1s promise convenience, but proof is still clinical. Ascletis’ ASC30 diabetes trial could test whether hype can meet HbA1c data.

Read More
Representative image of an oral obesity treatment concept illustrating how Eli Lilly and Company’s Foundayo approval could widen access to GLP-1 weight loss therapy and reshape the next phase of the obesity drug market.
Pharma & Biotech

Eli Lilly and Company’s Foundayo approval could widen the obesity market faster than rivals expected

Eli Lilly and Company’s Foundayo approval could reshape obesity treatment. Read what the oral GLP-1 launch changes for clinicians, payers, and rivals.

Read More
Pharma & Biotech

What Kailera Therapeutics and Hengrui Pharma’s Phase 2 ribupatide results reveal about oral GLP-1 viability

Can oral ribupatide reshape obesity treatment economics and adoption? Explore what Phase 2 data mean for GLP-1 pill strategies.

Read More
Pharma & Biotech

Amazon adds oral Wegovy to pharmacy platform: Will this reshape obesity care logistics?

Amazon Pharmacy now delivers oral Wegovy with insurance and cash-pay options. Find out how this reshapes GLP-1 access and obesity care.

Read More
Eli Lilly’s $6 billion API facility in Alabama raises the bar for U.S. peptide manufacturing
Pharma & Biotech

Eli Lilly’s $6bn API plant in Alabama signals new era in U.S. peptide drug manufacturing

Eli Lilly’s $6B Alabama facility will manufacture orforglipron and peptide APIs. Explore how this reshoring move could transform U.S. drug manufacturing.

Read More